Altria Group's Stock Price Surges Amid FDA Approval and Attractive Dividend Yield

sábado, 17 de enero de 2026, 7:27 pm ET1 min de lectura
MO--

Altria Group's stock has surged 10% in the past week and 6% YTD, outperforming the broader market. The FDA's approval of its on! Plus nicotine pouches could enhance its product offerings. Despite mixed analyst ratings, the stock's attractive dividend yield continues to draw income-focused investors. Analysts are divided, with five rating MO as a Buy, eight as Hold, and two as Sell.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios